7 benefits of using trimebutine Review article
Article Sidebar
Published:
Jun 30, 2015
Keywords:
trimebutine, irritable bowel syndrome, efficiency, tolerance
Main Article Content
Abstract
Irritable bowel syndrome (IBS) has been treated with trimebutine for many years. During this time we could observe high efficiency of trimebutine. Trimebutine is an effective treatment for abdominal pain and altered bowel habit, it means it is useful in all kinds of IBS. The tolerance of trimebutine is very good, and we don’t observe side effects of treatment very often.
Article Details
How to Cite
Soszka, A. (2015). 7 benefits of using trimebutine. Medycyna Faktow (J EBM), 8(2(27), 45-48. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2310
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Cremonini F., Talley N.J.: Irritable bowel syndrome: epidemiology, natural history health care seeking and emerging risk factors. Gastroenterol. Clin. North Am. 2005; 34: 189-204.
2. Gralnek I.M., Hays R.D., Kilbourne A. et al.: The impact of irritable bowel syndrome on health related quality of life. Gastroenterology 2000; 119: 654-660.
3. Fichna J., Storr M.A.: Brain-Gut Interactions in IBS. Front. Pharmacol. 2012; 3: 127.
4. Luiking Y.C., Akkermans L.M., Peeters T.L. et al.: Effects of motilin in human interdigestive gastrointestinal and gallbladder motility and involvement of 5HT3 receptors. Neurogastroenterol. Motil. 2002; 14: 151-159.
5. Taniyama K., Sano I., Nakayama S. et al.: Dual effect of trimebutine on contractility of the guinea pig ileum via the opioid receptors. Gastroenterology 1991; 1001: 1579-1587.
6. Fioramonti J., Fargeas M.J., Bueno L.: The involvement of opiate receptors in the effect of trimebutine on intestinal motility in the conscious dog. J. Pharm. Pharmacol. 1984; 36: 618-621.
7. Thompson W.G., Longstreth G.F., Drossman D.A. et al.: Functional bowel disorders and functional abdominal pain. Gut 1999; 45(supl. II): 43-47.
8. Roman F.J., Lanet S., Hamon J. et al.: Pharmacological Properties of Trimebutine and N-Monodesmethyltrimebutine. JPT 1999; 289: 1391-1397.
9. Okano H., Saeki S., Inui A. et al.: Effect of trimebutine maleate on emptying of stomach and gallbladder and release of gut following a solid meal on man. Dig. Dis. Sci. 1993; 38: 817-823.
10. Xue L., Fukuta H., Yamamoto Y. et al.: Dual effects of trimebutine on electrical responses of gastric smooth muscles in the rat. Eur. J. Pharmacol. 1995; 294: 75-81.
11. Harsawa S.: Effects of Cerekinon on the gastric emptying. Ther. Res 1985; 3: 782-787.
12. Kaptchuk T., Friedlander E., Kelley J.M. et al.: Placebo without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One 2010; 5: e15591.
13. Heaton K.W., Radvan J., Cripps H. et al.: Defecation frequency and timing, and stool form in the general population: a prospective study. Gut 1992; 33: 818-824.
14. Fioramonti J., Garcia-Villar R., Bueno L. et al.: Colonic myoelectrical activity and propulsion in the dog. Dig. Dis Sci 1980; 25: 641-646.
15. Drozda R., Grzegorczyk K., Słomka M. et al.: Trimebutyna – dlaczego jest przydatna w leczeniu zaburzeń czynnościowych przewodu pokarmowego? Terapia 2011; 5: 63-66.
2. Gralnek I.M., Hays R.D., Kilbourne A. et al.: The impact of irritable bowel syndrome on health related quality of life. Gastroenterology 2000; 119: 654-660.
3. Fichna J., Storr M.A.: Brain-Gut Interactions in IBS. Front. Pharmacol. 2012; 3: 127.
4. Luiking Y.C., Akkermans L.M., Peeters T.L. et al.: Effects of motilin in human interdigestive gastrointestinal and gallbladder motility and involvement of 5HT3 receptors. Neurogastroenterol. Motil. 2002; 14: 151-159.
5. Taniyama K., Sano I., Nakayama S. et al.: Dual effect of trimebutine on contractility of the guinea pig ileum via the opioid receptors. Gastroenterology 1991; 1001: 1579-1587.
6. Fioramonti J., Fargeas M.J., Bueno L.: The involvement of opiate receptors in the effect of trimebutine on intestinal motility in the conscious dog. J. Pharm. Pharmacol. 1984; 36: 618-621.
7. Thompson W.G., Longstreth G.F., Drossman D.A. et al.: Functional bowel disorders and functional abdominal pain. Gut 1999; 45(supl. II): 43-47.
8. Roman F.J., Lanet S., Hamon J. et al.: Pharmacological Properties of Trimebutine and N-Monodesmethyltrimebutine. JPT 1999; 289: 1391-1397.
9. Okano H., Saeki S., Inui A. et al.: Effect of trimebutine maleate on emptying of stomach and gallbladder and release of gut following a solid meal on man. Dig. Dis. Sci. 1993; 38: 817-823.
10. Xue L., Fukuta H., Yamamoto Y. et al.: Dual effects of trimebutine on electrical responses of gastric smooth muscles in the rat. Eur. J. Pharmacol. 1995; 294: 75-81.
11. Harsawa S.: Effects of Cerekinon on the gastric emptying. Ther. Res 1985; 3: 782-787.
12. Kaptchuk T., Friedlander E., Kelley J.M. et al.: Placebo without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One 2010; 5: e15591.
13. Heaton K.W., Radvan J., Cripps H. et al.: Defecation frequency and timing, and stool form in the general population: a prospective study. Gut 1992; 33: 818-824.
14. Fioramonti J., Garcia-Villar R., Bueno L. et al.: Colonic myoelectrical activity and propulsion in the dog. Dig. Dis Sci 1980; 25: 641-646.
15. Drozda R., Grzegorczyk K., Słomka M. et al.: Trimebutyna – dlaczego jest przydatna w leczeniu zaburzeń czynnościowych przewodu pokarmowego? Terapia 2011; 5: 63-66.